|
"Statistical
analysis revealed significant differences
between 6 and 24 months as an overall
cumulative and positive change of
the characteristics of cataracts
in the NAC-treated group, when compared
to the control group. The N-acetylcarnosine
eye drops are therefore proposed
as an effective and physiologically
acceptable drug for non-surgical
treatment of age-related and senile
cataracts. For the patients treated,
drug tolerance was good and no side
effects were associated with the
application of the 1% NAC formulation.
What is more, no recurrence of cataract
development occurred during the
period of NAC application."
Dr. Mark Babizhayev
- Contact
lens disorders
- Presbyopia.
- Corneal
disorders
- Eyestrain.
- Floaters
- Computer
vision syndrome (CVS).
- Ocular
inflammation.
- Blurred
vision.
- Dry
eye syndrome.
- Retinal
degeneration
- Diabetes
induced ocular disease
Nu-Eyes™ N-acetylcarnosine
eye drop's advanced anti-oxidant
properties were proven in Russian
trials, to reduce and protect the
crystalline lens from oxidative
stress-induced, cross-linking damage
which is believed to contribute
in the development of variety of
ocular conditions such as cataracts,
ocular inflammation, corneal disorders,
primary open angle glaucoma, vitreous
opacities and retinal disorders
My
Testimonial
- "My
eyes were so very dry, gritty and
blurry and hurt so much that I couldn't
even read the newspaper. Various
Eye drops from the store just seemed
to make things worse. But since
using Nu-Eyes eye lubricant drops,
I can read for hours on end, with
absolutely no discomfort. After
so many years of anguish, Nu-Eyes
is a true miracle - Thank you Dr.
Babizhayev!". - Stan (La Jolla,
CA) More
Testimonies
Scientific
Proof
-
- In a recent clinical trial, patients
suffering from cataracts we given
two drops of NAC in their effected
eye(s) twice daily for 6-months
with the following results: ·
90.1% of the patients were able
to see more clearly· 88.9%
of the patients had improved. The
results of this and supportive studies
indicate NU-EYES™ is a definitive
breakthrough in cataract reversal
and prevention!
Human
Clinical Trials
N-acetylcarnosine
was used in a clinical trial with
96 patients aged 60 and above. All
the patients had senile cataract
in various stages of maturity. The
duration of the disease in these
patients ranged between 2 and 21
years. The patients instilled 1
or 2 drops into each eye 3 - 4 times
a day, for a range of 3 to 6 months.
The results showed that there was
a pronounced effect on primary senile
cataract; the effective rate was
100% (i.e. all patients experienced
an improvement). For the more mature
senile cataract (i.e. those who
had had the cataract the longest
time, in some cases more than 20-years)
the effective rate was still an
extremely impressive 80%. Importantly,
it was also noted that there were
no side effects noted in any patients.
Another
Russian study was designed to document
and quantify the changes in lens
clarity over a 6 to 24 month period
for 49 volunteers. Their average
age was 65 and all suffered from
senile cataract of a minimal to
advanced opacification.
The patients received either the
NAC eye-drops or a placebo, 2-drops
in each twice daily. The patients
were then evaluated at 2 and 6-month
periods. 6-months - 88.9% of all
eyes treated with NAC had an improvement
of glare sensitivity), up to a 100%
improvement). 41.5% of all eyes
treated with NAC had a significant
improvement of the transmissivity
of the lens. Most importantly 90%
of the eyes treated with NAC showed
an improvement in visual acuity.
Importantly, this study also showed
that at 24-months the NAC treated
group, (who already had significant
improvement to the quality of their
eyesight), sustained these results
with the continued use of NAC eye-drops.
Again, no significant side effects
were noted in any cases throughout
the 2-year period.
The statistics in the human trials
show that Nu-Eyes eye-drops applied
for 6-months, (twice daily into
the eye), in patients all suffering
from senile cataract, had the following
results:
- 88.9%
had an improvement of glare sensitivity.
- 41.5%
had an improvement of the transmissivity
of the lens.
- 90%
had an improvement in visual acuity.
Additional
study conducted on patients without
cataracts between the ages of 48
and 60 who had various degrees of
eyesight impairment, without symptoms
of cataract, were tested. Results:
After a period of NAC use ranging
from two to six months, it was concluded
that NAC eye drops alleviated eye
tiredness and promoted clarity of
vision. Subjects reported that the
drops "brightened" and
"relaxed" their eyes.
These results are important as they
suggest that NAC eye drops can be
used effectively for general preventative
purposes also.
Animal
Trials
Once
laboratory testing was passed, and
the purity level established, N-Acetylcarnosine
was tested in the eyes of animals,
(specifically canines and rabbits).
These studies produced remarkably
fast results in the improvement
of clarity; glare sensitivity and
overall vision for the animals involved.
Furthermore, no serious side effects
were noted and the beneficial affects
were sustainable. Unsurprisingly,
these positive results in animals
are what led to the studies being
continued in humans.
 |
Can
I use Nu-Eyes™ for my
Dog with Cataracts?
"The
treatment of age-related cataracts
in canines and rabbits has
been conducted and the efficacy
of using N-acetylcarnosine
for cataract treatment was
established. In traumatic
and liposome-induced cataract
types the striking results
in canines and rabbits for
both cataract reversal and
prevention of lens opacities
are clear. Therefore these
data showed that N-acetylcarnosine
is effective in the management
of age related cataract reversal
and prevention both in human
eyes and in canine eyes.."
Mark Babizhayev MA., PhD. |
Many
dog owners are using this product
to effectively address their pet's
cataract condition including veterinarians.
While Nu-Eyes™ is widely used
and prescribed in Eastern Europe
in hospitals by physicians and veterinarians
it has not yet been FDA approved
in the US. All of the research over
the last 10 years has been conducted
in Russia and some in China; therefore
we are not allowed to make specific
recommendations although the results
in Russia were quite impressive
with canines with no negative side
affects as this is a natural compound.
The dosage for animals has not yet
been clearly defined so most pet
owners are following the same dosage
recommendation for humans and are
applying 3 to 4 drops per affected
eye daily. Remember also that the
use of any unapproved drug for your
animals should be discussed with
your veterinarian.
Note:
Innovative Vision Products' patented
methodology to produce a highly
specific purity level for NAC is
to date the only treatment that
has been proven in clinical trials
to be suitable for ophthalmic use
with high efficacy and excellent
physiological tolerance.
"Cataract
is a widespread age-related affliction
and NAC eye-drops appear to be a
highly efficacious and safe treatment
for cataract. As such, I suspect
that this supplement is going to
become one of the most important
new discoveries, and will have a
major impact on the way that cataract
is controlled." Mark
A. Babizhayev, MA, PhD.
Publication
Excerpts
N-Acetylcarnosine,
a natural histidine-containing dipeptide,
as a potent ophthalmic drug in treatment
of human cataracts.
1N-Acetylcarnosine
is indicated to treat ocular disorders,
which have the common component
of oxidative stress in their genesis
(Cataracts, Glaucoma, Retinal
Degeneration, Corneal disorders,
Ocular inflammation, complications
of Diabetes Mellitus, Systemic diseases).
1 See Babizhayev
et al., Clin Chim Acta 1997 Mar
18; 259(1-2): 199-201 Click
here
N alpha-acetylcarnosine is a
prodrug of L-carnosine in ophthalmic
application as antioxidant.
2The
advantage of the ophthalmic prodrug
N-acetylcarnosine and its bioactivated
principle L-carnosine as universal
antioxidants relates to the ability
to give efficient protection against
oxidative stress both in the lipid
phase of biological membranes and
in aqueous environments. N-Acetylcarnosine
is proposed for treatment of ocular
disorders that have a component
of oxidative stress in their genesis(Cataracts,
Glaucoma, Retinal Degeneration,
Corneal disorders, Ocular inflammation,
complications of Diabetes Mellitus,
Systemic diseases).
2 see Babizhayev et al.,
Biochemistry (Mosc). 2000 May;65(5):588-98.
Click
here
Antioxidant
activity of L-carnosine, a natural
histidine-containing dipeptide in
crystalline lens.
3 Oxidative stress caused
by free radicals is believed to
be one of the causes of the structural
and functional degradations of human
tissue during aging. Oxidative
stress is also believed to cause
much degenerative (ocular) pathology.
For example,
it is believed that in some forms
of cataract, especially those associated
with retinal disorders, lens clouding
is due to the diffusion of toxic
products from oxidation.
3
See Babizhayev et al., Biochimica
et Biophysica Acta, 1004 (1989),
124-133 and references cited therein.
Click
here
DISCLAIMER:
ALL INFORMATION IS EDUCATIONAL AND
DOES NOT, AND SHOULD NOT, REPLACE
THE ADVICE OF YOUR PHYSICIAN.
Published
Clinical Papers
Scientific
References:
Boldyrev
AA, Dupin AM, Bunin Aya, Babizhayev
MA, Severin SE "The antioxidative
properties of carnosine, a natural
histidine containing di-peptide."
Biochem. Inrern., 1987, 15/6, 1105-1113.
Babizhayev MA et al "N-Acetylcarnosine,
a natural histidine-containing di-peptide,
as a potent ophthalmic drug in treatment
of human cataracts." Peptides
(USA) 2001, 22(6): 979-994.
Babizhayev MA, Yermakova VN, Deyev
Al, Seguin M-C "Imidazole-containing
peptiomimetic NACA as a potent drug
for the medicinal treatment of age-related
cataract in humans." J. Anti-Aging
Medicine 2000, 2, 43-62.
Babizhayev MA, Yermakova VN, Semiletov
yu A, Deyev Al "The natural
histidine-containing di-peptide
N-acetylcarnosine as an antioxidant
for ophthalmic use." Biochemistry
(Moscow), 2000, 65, 588-598.
Babizhayev MA, Yermakova VN, Sakina
NL, Evstigneeva RP, Rozhkova EA,
Zheltukhina GA "N-Acetycarnosine
is a prodrug of L-carnosine in ophthalmic
application as antioxidant."
Clin. Chim. Acta., 1996, 254, 1-21.Babizhayev
MA, Bozzo Costa E "Composizioni
farmaceutiche contenenti N-acetilcarnosina
per il trattamento della cataratta."
A61K gruppo 37/00 cap 20122 MI 15.10.1993.
Italian patent.
Babizhayev MA, Bozzo Costa E "Pharmaceutical
compositions containing N-Acetylcarnosine
for the treatment of cataract."
European Patent PCT/EP 94/03340
10.10.1994 Ref. SCB 238 PCT.
Babizhayev MA, Seguin M-C, Gueyene
J, Evstigneeva RP, Ageyeva EA, Zheltukhina
GA "L-carnosine and carcinine
act as natural antioxidants with
hydroxyl-radical-scavenging and
lipid peroxidase activities."
Biochem J. 304, 509-516.
Babizhayev MA, "Antioxidant
activity of L-carnosine, a natural
histidine-containing di-peptide
in crystalline lens." Biochem.
Biophys. Acta., 1989, 1004, 363-371.
Babizhayev MA, Deyev Al "Lens
opacity induced by lipid peroxidation
products as a model of cataract
associated with retinal disease."
Biochim. Biophys. Acta., 1989, 1004,
124-133.
Babizhayev MA, Deyev Al "Free
radical oxidation of lipid and thiol
groups in genesis of cataract."
Biophysics (biofizika), 1986, 31,
119-125, Pergamon Journals Ltd.
Kantha S, Wada S, Tanaka H, Takeushi
M, Watabe S, Ochi H (1966), Biochem.
Biophys. Res. Commun. 223, 278-292.
Boldyrev AA, "Problems and
perspectives in studying the biological
role of carnosine."International
Center for Biotechnology, Department
of Biochemistry, Lomonosov, Moscow
State University.
Hipkiss A, (1998) Int. J. Biochem.
Mol. Biol., 30, 863-868.
Boldyrev AA, Dupin A, Bunin A, Babizhayev
MA, Severin SE (1987), Biochem.
Int., 15, 1107-1113.Wang AM, Ma
C, Xie H, F Shen "Medical application
of carnosine." Department of
Biochemistry and Neurobiology, Harbin
Medical University, China.
Go to theWorld Health Organisation,
Ageing and Health, Website to obtain
more information.
|
Product
Questions? 1.800.378.8428